Topic

All

11
Jun
2020

AstraZeneca Opens Its Digital Komono

AstraZeneca has emerged with a reputation as one of the industry’s most imaginative pharmas – it was named the “most innovative” global pharma company by IDEA Pharma in November 2019, and was cast as Gallant to GSK’s Goofus in a recent Financial Times piece examining their contrasting trajectories. In this context, I was especially excited when I saw what looked...
Read More
11
Jun
2020

Inconvenient Truths and Rays of Light

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
10
Jun
2020

Making Drugs at the Edge of Reason

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
5
Jun
2020

Tech Integration Into Pharma: A Report From The Front Line

Most biopharma companies can talk at some length about embracing data science, and sometimes it’s hard to get beneath the surface of what they’re doing, at least publicly. But it was my privilege recently to frame and moderate a very insightful recent conversation – recorded for on-demand viewing at this year’s virtual BIO 2020 conference. This provided an unusual opportunity...
Read More
4
Jun
2020

Anger, Pain, and Hope

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
2
Jun
2020

Digital Natives and Skilled Operators: Weaving Data Science Into Pharma R&D

An abiding challenge at the intersection of technology and pharma R&D is the need to bring together two historically disparate cultures.  Tech companies tend to be led by engineers. Pharma R&D is generally run by chemists and biologists in the early stages, and by physicians further on in development. Each of these domains has its own distinct language, culture and...
Read More
28
May
2020

The Infodemic Summer

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.